Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LX1606 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 500 mg LX606 | EXPERIMENTAL | All subjects will receive a single oral 500 mg dose of \[14C\]-LX1606. |
| Name | Type | Description |
|---|---|---|
| 500 mg [14C]-LX1606 | DRUG | 500 mg dose of LX1606 containing a target dose of 3.32 Megabecquerel (MBq) of radiation as \[14C\]-LX1606. |
Inclusion Criteria: * Healthy male subjects aged 30 to 65 years of age. * Male subjects and their partners must agree to use an adequate method of contraception * Historically able to produce a minimum of 1 bowel movement every day on most days Exclusion Criteria: * Female subjects * Use of any m...
LX1606 is an investigational small molecule being developed for carcinoid syndrome, a condition that can occur in patients with neuroendocrine tumors. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
LX1606 is being developed by Lexicon Pharmaceuticals, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol LXRX. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetics.
LX1606 is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. One Phase 1 trial has been completed, and the drug is not currently in active clinical trials.
LX1606 has one completed clinical trial, NCT01932528, an open-label study evaluating the absorption, metabolism, and excretion of [14C]-Telotristat Etiprate in males. The trial enrolled 8 participants in the United Kingdom and was not randomized or double-blinded.
LX1606 is also known as telotristat etiprate. The completed clinical trial NCT01932528 specifically studied [14C]-Telotristat Etiprate, which is the radiolabeled form of the drug used to track its absorption and metabolism in the body.